NEW YORK (GenomeWeb) – Reveal Biosciences has signed a deal to use Affymetrix's ViewRNA ISH products with tissue samples to provide RNA in situ hybridization staining, imaging, and quantification services in combination with its ImageDx image-analysis software, the companies announced today.
Specific terms of the deal were not disclosed.
"RNA in situ hybridization is fast becoming the method of choice for researchers wanting to validate established and novel biomarkers for translational and clinical research," Guy Afseth, marketing director for Affy's oncology portfolio, said in a statement.
"Our scientific expertise, combined with high-resolution imaging and our proprietary image analysis software … form a powerful platform for the localization and quantification of mRNA in tissue samples," Reveal Founder and CEO Claire Weston, added in the statement.
ViewRNA combines target-specific probe sets and branched DNA signal amplification for the detection of specific signals. ImageDx is designed to provide quantification data including percentage positivity and staining intensity over whole-slide images or single field or view images.